{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:06:41Z","timestamp":1789330001605,"version":"build-2803163510"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Medullary thyroid carcinoma (MTC) is a heterogeneous neuroendocrine malignancy in which outcomes are shaped by tumor burden, locoregional spread, and molecular context. Precision management therefore requires explicit separation of hereditary MTC driven by germline RET variants from presumed sporadic disease, and a structured integration of serum biomarkers, imaging, pathology, and genotype. This review synthesizes actionable evidence on calcitonin (Ctn) and carcinoembryonic antigen (CEA) baseline values and kinetics, universal germline RET testing, and tumor somatic profiling in advanced or progressive disease, and highlights desmoplastic stromal reaction (DSR) as an underused postoperative risk modifier in sporadic MTC. We propose a clinician-facing three-panel workflow: Panel A standardizes initial evaluation and mandates germline RET testing for all patients; Panel B outlines genotype- and staging-informed surgery and surveillance for hereditary disease, including pediatric carriers; and Panel C provides a staged approach for sporadic MTC in which imaging directs compartment selection and early postoperative DSR and biochemical response tailor surveillance intensity and thresholds for re-staging and re-intervention. By aligning decision nodes with real-world scenarios and using consistent surgical terminology, this framework offers a testable blueprint for precision surgery, surveillance stratification, and genotype-directed systemic therapy.<\/jats:p>","DOI":"10.3389\/fendo.2026.1794118","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:25:34Z","timestamp":1772688334000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Precision management of medullary thyroid carcinoma: a dynamic framework integrating biomarkers, genotyping, and risk stratification"],"prefix":"10.3389","volume":"17","author":[{"given":"Chengzheng","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Medicine, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology II, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology I, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianying","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003284","article-title":"Global burden of thyroid cancer in 2022: incidence and mortality estimates from GLOBOCAN","volume":"137","author":"Lyu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2703","article-title":"Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS","volume":"98","author":"Agrawal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1418657","article-title":"Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/CMAR.S440477","article-title":"Serum biochemical markers for medullary thyroid carcinoma: an update","volume":"16","author":"Liu","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153643","article-title":"Update on the diagnosis and management of medullary thyroid cancer: what has changed in recent years","volume":"14","author":"Kaliszewski","year":"2022","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1590","article-title":"Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules","volume":"92","author":"Costante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0391-4","article-title":"Desmoplastic stromal reaction in medullary thyroid cancer\u2014an intraoperative \u201cmarker\u201d for lymph node metastases","volume":"30","author":"Scheuba","year":"2006","journal-title":"World J Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaa047","article-title":"Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction","volume":"108","author":"Niederle","year":"2021","journal-title":"Br J Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"108881","DOI":"10.1016\/j.surg.2024.05.063","article-title":"Is desmoplastic stromal reaction useful to modulate lymph node dissection in sporadic medullary thyroid carcinoma","volume":"177","author":"Procopio","year":"2025","journal-title":"Surgery"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znad172","article-title":"Desmoplastic reaction in medullary thyroid carcinoma predicts presence of lymph node metastasis","volume":"110","author":"G\u00f3mez-Ram\u00edrez","year":"2023","journal-title":"Br J Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2368","article-title":"Biomarker-based risk stratification for previously untreated medullary thyroid cancer","volume":"95","author":"Machens","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03969-z","article-title":"Gender and tumor size-specific calcitonin cutoff value for diagnosing MTC in 10,618 patients with thyroid nodule surgery","volume":"86","author":"Ni","year":"2024","journal-title":"Endocrine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.12182\/20230160513","article-title":"Value of baseline calcitonin for differential diagnosis of medullary thyroid cancer","volume":"54","author":"Liu","year":"2023","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1094242","article-title":"Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: a retrospective study","volume":"13","author":"Jiao","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03666.x","article-title":"Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis","volume":"72","author":"Meijer","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0217","article-title":"Tumor grade predicts for calcitonin doubling times and disease-specific outcomes after resection of medullary thyroid carcinoma","volume":"32","author":"Nigam","year":"2022","journal-title":"Thyroid"},{"key":"B22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12957-024-03397-3","article-title":"Time kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma","volume":"22","author":"Guo","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1089\/thy.2012.0236","article-title":"Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma","volume":"23","author":"Frank-Raue","year":"2013","journal-title":"Thyroid"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab564","article-title":"Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma","volume":"106","author":"Giovanella","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.754565","article-title":"Basal and calcium-stimulated procalcitonin for the diagnosis of medullary thyroid cancers: lights and shadows","volume":"12","author":"Censi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2020.5407","article-title":"Significance of chromogranin A and synaptophysin in medullary thyroid carcinomas","volume":"21","author":"Tomita","year":"2021","journal-title":"Bosn J Basic Med Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113268","article-title":"Results and clinical interpretation of germline RET analysis in a series of patients with medullary thyroid carcinoma: the challenge of the variants of uncertain significance","volume":"12","author":"Innella","year":"2020","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12686","article-title":"Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer","volume":"82","author":"Romei","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318268301d","article-title":"Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system","volume":"257","author":"Machens","year":"2013","journal-title":"Ann Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"B37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41421-022-00479-y","article-title":"Integrated proteogenomic characterization of medullary thyroid carcinoma","volume":"8","author":"Shi","year":"2022","journal-title":"Cell Discov"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad051","article-title":"NF1 gene inactivation acts as a tumor driver in RET\/RAS-negative medullary thyroid carcinomas","volume":"188","author":"Ciampi","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae059","article-title":"Not only RET but NF1 and chromosomal instability are seen in young patients with sporadic medullary thyroid carcinoma","volume":"8","author":"Castroneves","year":"2024","journal-title":"J Endocr Soc"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1005467","DOI":"10.1371\/journal.pgen.1005467","article-title":"Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer","volume":"11","author":"Ji","year":"2015","journal-title":"PloS Genet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2025.0017","article-title":"First report of SPECC1L::ALK fusion in medullary thyroid carcinoma with remarkable response to alectinib","volume":"35","author":"Bischoff","year":"2025","journal-title":"Thyroid"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15195","article-title":"A comparison of the predictive value of International Medullary Thyroid Carcinoma Grading System (IMTCGS) with that of other risk factors in a Chinese medullary thyroid carcinoma cohort","volume":"102","author":"Ni","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11071","article-title":"Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer","volume":"106","author":"Machens","year":"2019","journal-title":"Br J Surg"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000112","article-title":"Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer","volume":"63","author":"Andrade","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/thy.2022.0295","article-title":"An undetectable postoperative calcitonin level is associated with long-term disease-free survival in medullary thyroid carcinoma: results of a retrospective cohort study","volume":"33","author":"Duval","year":"2023","journal-title":"Thyroid"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0564","article-title":"Survival and long-term biochemical cure in medullary thyroid carcinoma in Denmark 1997-2014: a nationwide study","volume":"29","author":"Mathiesen","year":"2019","journal-title":"Thyroid"},{"key":"B48","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.oraloncology.2013.03.443","article-title":"Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging","volume":"49","author":"Tuttle","year":"2013","journal-title":"Oral Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0087-4","article-title":"Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study","volume":"33","author":"Trimboli","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S183268","article-title":"Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997-2013: a nationwide study","volume":"11","author":"Mathiesen","year":"2019","journal-title":"Clin Epidemiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09683-8","article-title":"Prophylactic lateral neck dissection for medullary thyroid carcinoma is not associated with improved survival","volume":"28","author":"Spanheimer","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246226","article-title":"Prophylactic and early thyroidectomy in RET germline mutation carriers in pediatric and adult population: long-term outcomes of a series of 63 patients","volume":"14","author":"Torresan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2213-8587(15)00337-X","article-title":"Management of advanced medullary thyroid cancer","volume":"4","author":"Hadoux","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac222","article-title":"Pre- and post-operative circulating tumoral DNA in patients with medullary thyroid carcinoma","volume":"107","author":"Ciampi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107708","article-title":"Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer","volume":"219","author":"Chiacchiarini","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0574","article-title":"Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives","volume":"26","author":"Ceolin","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0604","article-title":"Comprehensive immune profiling of medullary thyroid cancer","volume":"30","author":"Pozdeyev","year":"2020","journal-title":"Thyroid"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa701","article-title":"Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: a large cohort study","volume":"106","author":"Shi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203469","article-title":"Holomics and artificial intelligence-driven precision oncology for medullary thyroid carcinoma: addressing challenges of a rare and aggressive disease","volume":"16","author":"Luvhengo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad173","article-title":"Natural history and predictive factors of outcome in medullary thyroid microcarcinoma","volume":"108","author":"Kesby","year":"2023","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1794118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:25:36Z","timestamp":1772688336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1794118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":62,"alternative-id":["10.3389\/fendo.2026.1794118"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1794118","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"1794118"}}